Rocket Pharmaceuticals Inc.
05/21/2026 | Press release | Distributed by Public on 05/21/2026 04:04
Proxy Results (Form 8-K)
| Item 5.07. |
Submission of Matters to a Vote of Security Holders.
|
The 2026 Annual Meeting of Stockholders of Rocket Pharmaceuticals, Inc. (the "Company") was held on May 20, 2026 (the "Annual Meeting"). At the Annual Meeting, there were present, in person or by proxy, holders of 80,774,659 shares of common stock, or approximately 74.02% of the total outstanding shares eligible to be voted. The holders present voted on the four proposals presented at the Annual Meeting as follows.
Proposal One - Election of Directors
The Company's stockholders approved the election of seven directors to the Company's Board of Directors ("Board") by the following votes:
|
Nominee
|
Votes For
|
Votes Withheld
|
Broker Non-Votes
|
|
Peter Fong, M.D.
|
62,067,824
|
1,216,320
|
17,490,515
|
|
Carsten Boess
|
62,711,345
|
572,799
|
17,490,515
|
|
Mikael Dolsten, M.D., Ph.D.
|
59,500,907
|
3,783,237
|
17,490,515
|
|
Fady Malik, M.D., Ph.D.
|
62,755,875
|
528,269
|
17,490,515
|
|
Gaurav Shah, M.D.
|
62,808,593
|
475,551
|
17,490,515
|
|
David P. Southwell
|
43,172,112
|
20,112,032
|
17,490,515
|
|
Roderick Wong, M.D.
|
62,699,331
|
584,813
|
17,490,515
|
Proposal Two - Ratification of Appointment of Independent Registered Accounting Firm
The Company's stockholders ratified the appointment of EisnerAmper LLP as the Company's independent registered accounting firm for the fiscal year ending December 31, 2026 by the following votes:
|
Votes For
|
|
Votes Against
|
|
Abstentions
|
|
79,195,009
|
|
1,002,656
|
|
576,994
|
Proposal Three - Non-Binding Advisory Vote on the Compensation of the Company's Named Executive Officers
The Company's stockholders approved, on a non-binding, advisory basis, the compensation of the Company's named executive officers, as disclosed in the 2026 Proxy Statement pursuant to Section 14A of the Exchange Act (the "2026 Proxy Statement"). The final votes were:
|
Votes For
|
|
Votes Against
|
|
Abstentions
|
|
Broker Non-Votes
|
|
61,389,376
|
|
1,671,016
|
|
223,752
|
|
17,490,515
|
Proposal Four - Stock Option Exchange Program
The Company's stockholders approved the proposed stock option exchange program as described in the 2026 Proxy Statement. The final votes were:
|
Votes For
|
|
Votes Against
|
|
Abstentions
|
|
Broker Non-Votes
|
|
45,582,445
|
|
17,615,213
|
|
86,486
|
|
17,490,515
|
Rocket Pharmaceuticals Inc. published this content on May 21, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on May 21, 2026 at 10:05 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]